Research breakthroughs begin with questions—and the commitment to finding answers. In August 2025, The IBC Network Foundation proudly awarded a $100,000 research grant toDr. Filipa Lynce at Dana-Farber Cancer Institute to support an innovative study investigating the...
Editor’s Note: This article was developed from a podcast conversation and has been edited for clarity, readability, and length while preserving the original insights and intent of the discussion. In recent months, many inflammatory breast cancer (IBC) patients...
Blog by Trish Vickery On April 11, the Dana Farber IBC team held their annual patient forum; the virtual format allowed patients near and far to join. The day included informative medical presentations, followed by an expert roundtable, with a new feature –...
The FDA has approved vepdegestrant (Veppanu) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who have progressed after at least one line of endocrine therapy. Angela Alexander, PhD, Sr Clinical Studies Coordinator –...
by Terry Lynn Arnold Too many women newly diagnosed with stage IV inflammatory breast cancer (IBC) are being told that the type of cancer no longer matters. That statement should raise serious questions. Because it’s not true. IBC Is Different—From the Very Beginning...
Article by Dr. Angela Alexander On Apr 30th, the FDA approved a new first-in-class drug for the treatment of ER+ metastatic breast cancer (MBC). The new drug Vepdegestrant was approved only for patients with tumors that harbor ESR1 mutations, based on results from...
